Navigation Links
New Treatment For Obstructive Sleep Apnea Now Available In Canada
Date:11/19/2012

SAN JOSE, Calif. and TORONTO, Nov. 19, 2012 /PRNewswire/ -- Ventus Medical is pleased to announce the introduction of its proprietary Provent® Sleep Apnea Therapy into Canada. Provent Therapy is an innovative, non-invasive treatment for obstructive sleep apnea (OSA). Provent Therapy is now available in the province of Ontario and will be available throughout Canada by June 2013. ioSleep, Inc. is the strategic distribution partner of Provent Therapy in Canada.

(Photo: http://photos.prnewswire.com/prnh/20121119/SF15670)

(Logo: http://photos.prnewswire.com/prnh/20120712/LA37941LOGO)

There is growing demand for clinically proven sleep apnea treatments and the introduction of Provent represents a scientifically validated, innovative and user-friendly approach. Provent works across mild, moderate, and severe OSA and utilizes nasal expiratory positive airway pressure (EPAP) to keep a patient's airway open during sleep.

"According to the Public Health Agency of Canada over 1 in 4 Canadian adults are at high risk of having OSA.  OSA is suspected in patients who are loud snorers, excessively sleepy, obese and hypertensive," said Dr. John Fleetham, Professor of Medicine at the University of British Columbia. "OSA is increasingly being recognised in Canadian patients.  CPAP (continuous positive airway pressure) is the primary treatment for OSA, however not all patients can tolerate it as a long term treatment." Dr. Fleetham further comments, "I welcome new validated treatment alternatives for OSA such as Provent Sleep Apnea Therapy."

"We believe clinically-proven Provent Therapy offers a unique and convenient alternative to CPAP treatment for the large number of people in Canada currently affected by OSA," said Philip Westbrook, M.D., chief medical officer of Ventus Medical. "Provent has been used effectively in the United States since 2008 and in clinical studies, Provent Therapy improved quality of sleep while it reduced apnea (breathing disruptions), daytime sleepiness and snoring. Importantly, Provent is easy to use, portable and discreet for use at home or when travelling."

CPAP is the primary treatment of OSA and is extremely effective if worn as directed. However, up to half of all patients are not compliant with CPAP therapy due to the cumbersome nature of the treatment. Provent Therapy was developed to help patients who cannot tolerate CPAP therapy and will benefit from the small, non-invasive and effective technology, which Provent Therapy provides.

In patients with OSA the airway collapses during sleep when the muscles that hold it open relax. People with this disorder stop breathing during sleep---in some cases hundreds of times each night---usually for periods of ten seconds or longer. OSA can lead to fatigue, early morning headaches, irritability, lack of concentration, and contributes to depression, learning and memory difficulties, and sexual dysfunction. Importantly, recent studies have shown that OSA is associated with high blood pressure, irregular heartbeat, heart attack, stroke and diabetes.

"As we look at global market opportunities for Provent Therapy, Canada fits directly into our corporate strategy, which is to target markets where three factors come together: high prevalence of OSA, acceptance of innovative therapies, and importantly, a need for new therapeutic options that address low patient compliance," stated Peter Wyles, President and Chief Executive Officer of Ventus Medical. "With ioSleep and their extensive experience in sleep disorder treatment and diagnosis, we are pleased to present Provent Therapy as a new treatment to manage this troubling condition."

About Provent® Sleep Apnea Therapy

Provent is a proprietary medical device used for the treatment of OSA. The device has been shown to be clinically effective in a series of peer reviewed studies. It is an easy to use, non-invasive and disposable treatment that works across mild, moderate, and severe OSA. Provent Therapy utilizes nasal expiratory positive airway pressure (EPAP) to keep a patient's airway open during sleep and has been clinically proven in numerous studies to reduce sleep apnea. It incorporates a novel MicroValve design that is placed over the nostrils and secured with hypoallergenic adhesive. During inhalation, the valve opens allowing nearly unobstructed airflow. During exhalation, the valve closes, limiting airflow through small openings, which increases expiratory pressure and keeps the airway open, preventing disruption in breathing. Provent Therapy is approved by Health Canada, is FDA cleared and has CE marking. For more information, please visit www.proventtherapy.ca

About Ventus Medical

Ventus Medical is a privately-held medical device company dedicated to providing non-invasive medical solutions for people with sleep-disordered breathing. Based on its innovative MicroValve technology and patented designs, Ventus has developed a unique line of clinically-proven medical devices to address the continuum of sleep disorders from severe obstructive sleep apnea (OSA) to mild snoring. Ventus Medical devices work by creating expiratory positive airway pressure (EPAP). The company markets Provent® Therapy, a discreet, easy-to-use nasal device, for the treatment of OSA in the United States, Australia, New Zealand, Hong Kong, Singapore and Malaysia, and also markets an over-the-counter device for snoring in the United States. www.ventusmedical.com.

About ioSleep Inc.

ioSleep is a Canadian distributor of innovative solutions for patients suffering from sleep disorders.   Dedicated to supporting both the Canadian healthcare professional and patients with clinically effective treatment options to achieve healthy sleep.  A partner that provides custom solutions that best meets the patient's needs.  www.iosleep.com


'/>"/>
SOURCE Ventus Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... as president, effective Aug. 7, 2017. ... to pursue other interests and will serve as president emeritus ... has served us in multiple leadership roles since he joined ... 2015 and has provided decisive, strategic leadership which continues to ...
(Date:8/3/2017)... -- Opioid addiction and other drugs of abuse, blood poisoning ... outcomes, were problems taken on directly as laboratory professionals, ... them, met this week. This according to Kalorama Information. ... abuse, procalcitonin and acute kidney injury were key focuses ... in San Diego, CA.  Mechanisms ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5 ... , The healthcare industry in the United States has undergone major changes over the ... needing to have a doctor’s order to get a blood test or other lab ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... August 16, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, Prache ... effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , “Prache ...
(Date:8/16/2017)... ... ... Chain”: an inspirational story for those shackled by the chains of a broken life. ... writer and a woman of great faith and wisdom. She is a great motivational ... born and raised in Vero Beach, Florida and has dedicated her life and ministry to ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... of disease. It’s reaching out to a patient who feels isolated. It’s developing ... amid madness. , WesternU President Daniel R. Wilson, MD, PhD, invited three renowned ...
Breaking Medicine News(10 mins):